Behzad Aghazadeh - 23 Jul 2026 Form 4 Insider Report for Scribe Therapeutics, Inc. (SCTX)

Reporting relationship: Director, Other*
Issuer ticker: SCTX
Reported as of: 23 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jul 2026, 21:04:25 UTC
Prior SEC filing: 15 Jun 2026
Next SEC filing: 28 Jul 2026
Source filing: View source filing
Reporting owner signature: Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer

Key filing fact

Behzad Aghazadeh filed Form 4 for Scribe Therapeutics, Inc. (SCTX) on 27 Jul 2026.

Key facts

This page summarizes Behzad Aghazadeh's Form 4 filing for Scribe Therapeutics, Inc. (SCTX).
1 reported transaction and 3 derivative rows are listed below.
Accepted by SEC: 27 Jul 2026, 21:04.

Change

Previous filing in this sequence was filed on 15 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0001701815 Primary reporting owner

Aghazadeh Behzad

Relationship: Director, Other*
Address: C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK
Signature: Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer
Signature date: 27 Jul 2026

CIK 0001633313

Avoro Capital Advisors LLC

Relationship: Director, Other*
Address: 110 GREENE STREET, SUITE 800, NEW YORK
Signature: Avoro Ventures LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer
Signature date: 27 Jul 2026

CIK 0001879253

Avoro Ventures LLC

Relationship: Director, Other*
Address: 110 GREENE STREET, SUITE 800, NEW YORK
Signature: /s/ Behzad Aghazadeh
Signature date: 27 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SCTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +14,725
Change %
Price: $0.000000^*
Shares after: 14,725
Date: 23 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,725
Exercise price: $15.00
Footnotes: F1, F2, F3

SCTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +14,725
Change %
Price: $0.000000^*
Shares after: 14,725
Date: 23 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,725
Exercise price: $15.00
Footnotes: F1, F2, F3

SCTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +14,725
Change %
Price: $0.000000^*
Shares after: 14,725
Date: 23 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,725
Exercise price: $15.00
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to Behzad Aghazadeh's ("Dr. Aghazadeh") provision of service to the Issuer on each vesting date.

Footnote F2

This Form 4 is filed by Dr. Aghazadeh, Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), and Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures," together with Dr. Aghazadeh and Avoro Capital Advisors, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.

Footnote F3

The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC remarks

Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.